Skip to content

In the BioHarmony Drug Report Database

Belinostat

Beleodaq (belinostat) is a small molecule pharmaceutical. Belinostat was first approved as Beleodaq on 2014-07-03. It is used to treat t-cell lymphoma peripheral in the USA. It is known to target histone deacetylase 8, histone deacetylase 7, histone deacetylase 9, histone deacetylase 4, histone deacetylase 6, histone deacetylase 1, histone deacetylase 3, histone deacetylase 5, and histone deacetylase 2. Beleodaq's patents are valid until 2027-10-27 (FDA).
Trade Name Beleodaq
Common Name Belinostat
Indication t-cell lymphoma peripheral
Drug Class Enzyme inhibitors: inhibitors of histone deacetylase
Belinostat
Get full access now